Misty Shields
Internal Medicine · Indianapolis, INNPI 1699120824
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 55.7% of the total. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $643.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$22K
- AstraZeneca$12K
- Astrazeneca UK Limited$4K
- Pharmacosmos Therapeutics Inc.$479
- Genentech USA, Inc.$430
- Medtronic$143
- plus $358 from 9 others
Across 14 payments — averaging $26,576 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$196K
- Amgen$134K
- Puma Biotechnology, Inc.$41K
- Boehringer Ingelheim International GmbH$785
- Boehringer Ingelheim Pharma GmbH & Co.kg$436
What the payments were for
- Consulting fees$15,93341%
- Speaking & faculty fees$16,29041%
- Travel & lodging$3,3479%
- Food & beverage$3,6079%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 32 | $21,858 |
| AstraZeneca | 9 | $11,988 |
| Astrazeneca UK Limited | 2 | $4,020 |
| Pharmacosmos Therapeutics Inc. | 3 | $479 |
| Genentech USA, Inc. | 5 | $430 |
| Medtronic | 1 | $143 |
| Seagen Inc. | 1 | $100 |
| Catalyst Pharmaceuticals, Inc. | 1 | $57 |
| Daiichi Sankyo Inc. | 1 | $50 |
| Genentech, Inc. | 1 | $38 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Regeneron | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Amgen | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,277 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 28 | $398 |
| Prochlorperazine Maleate | 25 | $229 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Indianapolis
- Raj VuppalanchiIndianapolis$279K
- Napoleon MamintaIndianapolis$116K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Awaneesh KumarIndianapolis$68K
- Justin FieldIndianapolis$49K
- Volodymyr OliynykIndianapolis$38K
- Sapan BhutaIndianapolis$30K
- Azizullah BeranIndianapolis$29K
- Rachel WesterIndianapolis$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.